BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

859 related articles for article (PubMed ID: 8521759)

  • 1. Prevention of complications in non-insulin-dependent diabetes mellitus (NIDDM).
    Wolffenbuttel BH; van Haeften TW
    Drugs; 1995 Aug; 50(2):263-88. PubMed ID: 8521759
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oral antidiabetic agents: current role in type 2 diabetes mellitus.
    Krentz AJ; Bailey CJ
    Drugs; 2005; 65(3):385-411. PubMed ID: 15669880
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oral antidiabetic drugs: an overview.
    Melander A
    Diabet Med; 1996 Sep; 13(9 Suppl 6):S143-7. PubMed ID: 8894498
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacologic treatment options for non-insulin-dependent diabetes mellitus.
    Tan GH; Nelson RL
    Mayo Clin Proc; 1996 Aug; 71(8):763-8. PubMed ID: 8691897
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Drug therapy in subjects with impaired glucose tolerance].
    Kawamori R; Yoshii H
    Nihon Rinsho; 1996 Oct; 54(10):2750-3. PubMed ID: 8914439
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oral antihyperglycaemics. Considerations in older patients with non-insulin-dependent diabetes mellitus.
    Jennings PE
    Drugs Aging; 1997 May; 10(5):323-31. PubMed ID: 9143853
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacological regulation of blood glucose levels in non-insulin-dependent diabetes mellitus.
    Bressler R; Johnson DG
    Arch Intern Med; 1997 Apr; 157(8):836-48. PubMed ID: 9129543
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacologic therapy for type 2 diabetes mellitus.
    DeFronzo RA
    Ann Intern Med; 1999 Aug; 131(4):281-303. PubMed ID: 10454950
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Management of non-insulin-dependent diabetes mellitus.
    Lefèbvre PJ; Scheen AJ
    Drugs; 1992; 44 Suppl 3():29-38. PubMed ID: 1280575
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antihyperglycaemic agents. Drug interactions of clinical importance.
    Scheen AJ; Lefèbvre PJ
    Drug Saf; 1995 Jan; 12(1):32-45. PubMed ID: 7741982
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of alpha-glucosidase inhibitor (acarbose) combined with sulfonylurea or sulfonylurea and metformin in treatment of non-insulin-dependent diabetes mellitus.
    Vannasaeng S; Ploybutr S; Nitiyanant W; Peerapatdit T; Vichayanrat A
    J Med Assoc Thai; 1995 Nov; 78(11):578-85. PubMed ID: 8576667
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acarbose for the treatment of type II diabetes: the results of a Canadian multi-centre trial.
    Josse RG
    Diabetes Res Clin Pract; 1995 Aug; 28 Suppl():S167-72. PubMed ID: 8529510
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug treatment of non-insulin-dependent diabetes mellitus in the 1990s. Achievements and future developments.
    Scheen AJ
    Drugs; 1997 Sep; 54(3):355-68. PubMed ID: 9279500
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative tolerability profiles of oral antidiabetic agents.
    Krentz AJ; Ferner RE; Bailey CJ
    Drug Saf; 1994 Oct; 11(4):223-41. PubMed ID: 7848543
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
    Plosker GL; Figgitt DP
    Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of insulin and other antihyperglycaemic agents on lipid profiles of patients with diabetes.
    Chaudhuri A; Dandona P
    Diabetes Obes Metab; 2011 Oct; 13(10):869-79. PubMed ID: 21569185
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Efficacy of combination therapy of alpha-glucosidase inhibitor and insulin sensitizer in patients with type 2 diabetes].
    Kitaoka H
    Nihon Rinsho; 2002 Sep; 60 Suppl 9():464-9. PubMed ID: 12387035
    [No Abstract]   [Full Text] [Related]  

  • 18. Drug interactions of clinical importance with antihyperglycaemic agents: an update.
    Scheen AJ
    Drug Saf; 2005; 28(7):601-31. PubMed ID: 15963007
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical experience with acarbose as first line therapy in NIDDM.
    Fölsch UR
    Clin Invest Med; 1995 Aug; 18(4):312-7. PubMed ID: 8549018
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acarbose. An update of its pharmacology and therapeutic use in diabetes mellitus.
    Balfour JA; McTavish D
    Drugs; 1993 Dec; 46(6):1025-54. PubMed ID: 7510610
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 43.